Trial Profile
Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Bamlanivimab (Primary) ; Casirivimab/imdevimab (Primary) ; Sotrovimab (Primary)
- Indications COVID 2019 infections; Nosocomial infections
- Focus Therapeutic Use
- Acronyms CATCO-NOS
- 14 Apr 2023 Status changed from suspended to discontinued.
- 30 Nov 2021 Status changed from recruiting to suspended.
- 28 Sep 2021 Sotrovimab intravenous infusion has been added to the study regimen.